Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine

Mou,Yongbin; Xie,Hao; Huang,Xiaofeng; Han,Wei; Ni,Yanhong; Su,Hang; Wang,Zhiyong; Hu,Qingang

doi:10.3892/ol.2013.1633

Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine

Authors:
- Yongbin Mou
- Hao Xie
- Xiaofeng Huang
- Wei Han
- Yanhong Ni
- Hang Su
- Zhiyong Wang
- Qingang Hu
View Affiliations

Affiliations: Center Laboratory of Stomatology, Stomatological Hospital Affiliated Medical School, Nanjing University, Nanjing, Jiangsu 210008, P.R. China, Institute of Life Sciences, The Key Laboratory of Developmental Genes and Human Disease, Southeast University, Nanjing, Jiangsu 210096, P.R. China
Published online on: October 15, 2013 https://doi.org/10.3892/ol.2013.1633
Pages: 1799-1803

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The successful treatment of cancer with dendritic cell (DC) tumor vaccine is highly dependent on the efficacy of antigen presentation and T cell activation. In the present study, a novel vaccine of DCs fused with autologous tumor cells was introduced, which had a marked ability to suppress head and neck carcinoma. DCs generated from the bone marrow of mice were fused with an autologous tumor cell line using polyethylene glycol (PEG). To observe the fused cells, confocal microscopy and FACS analysis were performed. Subsequently, the activation and proliferation of T cells, as well as animal experiments, were examined. The efficiency of DC/tumor fusion was 18.03% and T cells were well-activated by the hybrids. The volumes of tumors on the tumor-bearing mice were controlled, survival time of tumor-bearing mice was prolonged and the level of IFN-γ in serum was significantly increased compared with the control group and lysate-pulsed DC group. The results indicate that the DC/tumor fusion vaccine appears to be more effective than DCs pulsed with tumor lysate for the treatment of head and neck carcinoma, which may be useful in future clinical studies.

View Figures

View References

1	Steinman RM and Banchereau J: Taking dendritic cells into medicine. Nature. 449:419–426. 2007. View Article : Google Scholar : PubMed/NCBI
2	Banchereau J and Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 5:296–306. 2005. View Article : Google Scholar : PubMed/NCBI
3	Iwahashi M, Katsuda M, Nakamori M, et al: Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8⁺ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci. 101:2510–2517. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kono K, Mizukami Y, Daigo Y, et al: Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 100:1502–1509. 2009. View Article : Google Scholar : PubMed/NCBI
5	Turtle CJ and Riddell SR: Genetically retargeting CD8⁺ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol. 23:299–305. 2011. View Article : Google Scholar : PubMed/NCBI
6	Villarroel-Dorrego M, Speight PM and Barrett AW: Expression of major histocompatibility complex class II and costimulatory molecules in oral carcinomas in vitro. Med Oral Patol Oral Cir Bucal. 10:188–195. 2005.PubMed/NCBI
7	Mimura K, Ando T, Poschke I, et al: T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer. 128:390–401. 2011. View Article : Google Scholar : PubMed/NCBI
8	Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J and Sabzevari H: Amplification of the lytic potential of effector/memory CD8⁺ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther. 11:665–680. 2004.PubMed/NCBI
9	Malvicini M, Alaniz L, Bayo J, et al: Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. Oncoimmunology. 1:1038–1047. 2012. View Article : Google Scholar : PubMed/NCBI
10	O’Neill DW, Adams S and Bhardwaj N: Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 104:2235–2246. 2004.PubMed/NCBI
11	Xu Q, Liu G, Yuan X, et al: Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells. 27:1734–1740. 2009. View Article : Google Scholar : PubMed/NCBI
12	Williams BJ, Bhatia S, Adams LK, et al: Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. PLoS One. 7:e469812012. View Article : Google Scholar : PubMed/NCBI
13	Noguchi T, Kato T, Wang L, et al: Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res. 72:1672–1682. 2012. View Article : Google Scholar : PubMed/NCBI
14	Lee WT: Dendritic cell-tumor cell fusion vaccines. Adv Exp Med Biol. 713:177–186. 2011. View Article : Google Scholar : PubMed/NCBI
15	Mou Y, Chen B, Zhang Y, et al: Influence of synthetic superparamagnetic iron oxide on dendritic cells. Int J Nanomedicine. 6:1779–1786. 2011.PubMed/NCBI
16	Benencia F, Courrèges MC and Coukos G: Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med. 6:212008. View Article : Google Scholar : PubMed/NCBI
17	Mou Y, Hou Y, Chen B, et al: In vivo migration of dendritic cells labeled with synthetic superparamagnetic iron oxide. Int J Nanomedicine. 6:2633–2640. 2011.PubMed/NCBI
18	Verdijk P, Aarntzen EH, Lesterhuis WJ, et al: Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res. 15:2531–2540. 2009. View Article : Google Scholar : PubMed/NCBI
19	Creusot RJ, Yaghoubi SS, Chang P, et al: Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells. Blood. 113:6638–6647. 2009. View Article : Google Scholar : PubMed/NCBI
20	Huck SP, Tang SC, Andrew KA, Yang J, Harper JL and Ronchese F: Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8⁺ T cells against tumors. Cancer Immunol Immunother. 57:63–71. 2008. View Article : Google Scholar : PubMed/NCBI
21	Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H and Shu S: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother. 27:265–272. 2004. View Article : Google Scholar : PubMed/NCBI
22	Hu Z, Liu S, Mai X, Hu Z and Liu C: Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice. Cell Immunol. 262:112–119. 2010. View Article : Google Scholar
23	Deng YJ, Zhang LJ, Su XD, et al: Dendritic cell-tumor cell fusion vaccine prevents growth of subcutaneous transplanted esophageal carcinomas. Ai Zheng. 28:1067–1071. 2009.(In Chinese).
24	Koido S, Tanaka Y, Chen D, Kufe D and Gong J: The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol. 168:2111–2117. 2002. View Article : Google Scholar : PubMed/NCBI
25	Koido S, Hara E, Torii A, et al: Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells. Int J Cancer. 117:587–595. 2005. View Article : Google Scholar : PubMed/NCBI
26	Koido S, Ohana M, Liu C, et al: Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. Clin Immunol. 113:261–269. 2004. View Article : Google Scholar : PubMed/NCBI
27	Phan V, Errington F, Cheong SC, et al: A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med. 9:1215–1219. 2003. View Article : Google Scholar : PubMed/NCBI